growth. Clinical trials are already underway to assess various immunotherapy approaches, such As Immune Checkpoint Inhibitors (ICIs), vaccines, chimeric antigen receptor T-cell (CAR-T cell) therapy, and virus-based
different types of cancer. Some of the most notable ones include pembrolizumab and nivolumab (checkpoint inhibitors), as well as CAR T-cell therapies like Kymriah and Yescarta. Immunotherapy has shown
aimed at preserving beta cell mass and function have gained traction. Monoclonal antibodies, immune checkpoint inhibitors, and other immunomodulatory agents show potential in halting or slowing autoimmune destruction…
potential therapeutic vulnerabilities. Furthermore, we explore various therapeutic modalities, including synthetic lethality, immune checkpoint inhibitors, and gene therapy, designed to exploit the consequences of tumor…
events. After systemic drug treatment (tyrosine kinase inhibitors alone or in combination with immune checkpoint inhibitors), the therapeutic efficacy was evaluated based on RECIST 1.1 criteria. COX regression model
mCRC), pembrolizumab, nivolumab, and ipilimumab are the currently authorized first and second-line immune checkpoints. But the problem instead concerns tumors with Microsatellite Stability (MSS or MSI-L) where
ways in which these innovative approaches are reshaping the field of medicine. From checkpoint inhibitors to personalized vaccines, these advancements are unlocking the full potential of the immune system
immune system to recognize and eliminate cancer cells or target malfunctioning immune responses. Immune checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccines are some of the game-changing immunotherapies
explain the lack of effective therapy for gliomas. However, immunotherapy, which includes blocking immune checkpoint inhibitors, has increased patient survival in several cancer types (Hend
harm to healthy tissues. Various modalities, including small molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors, are discussed, along with their distinct mechanisms of action. The review…
metastatic brain tumor with a low success rate in treatment, particularly in immune checkpoint-active tumors, resulting in less than three percent of patients surviving beyond five years. Targeted treatments
genetic engineering to create tumour antigen-specific T cells. Recently, mAbs that block key checkpoints on T cells have improved survival in metastatic melanoma and induced antitumor effects in other
daughter cells. The cell cycle is tightly regulated by a network of proteins and checkpoints, ensuring accurate progression and preventing errors. Dysregulation of the cell cycle can lead to diseases
fidelity of DNA replication is crucial. Cells have built-in regulatory mechanisms and checkpoints that monitor the replication process, detecting and correcting any errors or abnormalities. These safeguards help ensure
gained more and more interest. Clinical trials are already testing immunotherapy approaches including Immune Checkpoint Inhibitors (ICIs), vaccinations, and Chimeric Antigen Receptor T-Cells (CAR-T). Treatment using…
different types of cancer. Some of the most notable ones include pembrolizumab and nivolumab (checkpoint inhibitors), as well as CAR T-cell therapies like Kymriah and Yescarta. Immunotherapy has shown
transformative impact on cancer care. We discuss the principles behind immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, and their specific applications in orthopedic…
abstract discusses the potential of targeting non-coding RNAs, epigenetic modifications, and immune checkpoints as novel therapeutic opportunities. These emerging areas present promising avenues for developing…
unique characteristics of ADCs and synergizing with other immuno-oncology modalities, such as immune checkpoint inhibitors and adoptive cell therapies, ADCs hold the promise of improving outcomes for cancer patients
this study is to examine the efficacy and safety of immune checkpoint inhibitors (ICIs) as a treatment for advanced nonsmall cell lung cancer (NSCLC). Neo-antigens are significant biomarkers
impact of immunotherapy. Immunotherapy utilizes different strategies to enhance the immune response against cancer. Checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, release the brakes on the immune
impact of immunotherapy. Immunotherapy utilizes different strategies to enhance the immune response against cancer. Checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, release the brakes on the immune
cases. NSCLC cells can evade the immune system, but immunotherapy drugs such as checkpoint inhibitors can help to activate T cells and enhance immune response against cancer cells. While
different types of cancer. Some of the most notable ones include pembrolizumab and nivolumab (checkpoint inhibitors), as well as CAR T-cell therapies like Kymriah and Yescarta. Immunotherapy has shown
treatment of various types of cancer. It discusses key immunotherapeutic strategies, including immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, highlighting their mechanisms of action…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.